病人想什么和病人做什么:在性结肠炎中,安慰剂,nocebo和治疗坚持
Emanuela Ribichini1, Giorgia Burrelli Scotti1, Simone Di Cola1
1Department of Translational and Precision Medicine, Sapienza University, 00185 Rome, Italy.
Journal of clinical medicine
|June 26, 2025
概括
患者的态度和情绪反应显著影响性结肠炎 (UC) 治疗的坚持. 了解安慰剂和安慰剂效应是改善UC患者长期治疗结果的关键.
科学领域:
- 胃肠病学 胃肠病学
- 精神病体医学是一种精神病体医学.
- 临床药房 临床药房
背景情况:
- 患者坚持治疗对于成功的长期治疗性结肠炎 (UC) 至关重要.
- 影响坚持的因素包括患者的信念,对药物的不良影响的担忧,以及患者与提供者的互动.
- 情绪态度和期望有助于安慰剂和nocebo效应,影响治疗坚持和结果.
研究的目的:
- 批判性地审查性结肠炎 (UC) 治疗的坚持.
- 探索治疗的情感组成部分与安慰剂/安慰剂效应之间的相互作用.
- 了解患者行为机制,以优化UC治疗.
主要方法:
- 现有文献的叙述性审查.
- 对影响患者在UC中的坚持因素的分析.
- 在UC治疗中研究安慰剂和无效疗法的作用.
主要成果:
- 患者的态度和情绪因素显著影响了对UC治疗的坚持.
- 安慰剂和安慰剂效应是重要的混因素,特别是在患者报告的结果中.
- 在临床实践中,安慰剂效应的治疗效益与临床实践有关,尽管数据有限.
结论:
- 了解患者行为的心理基础对于UC管理至关重要.
- 基于个体患者心理学的治疗方法和时间表的优化可以改善患者的坚持和结果.
- 需要进一步的研究来量化安慰剂效应在常规UC护理中的影响.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
The Placebo Effect
6.3K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.3K
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
430
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
430
Drugs for Treatment of Constipation-Predominant IBS
353
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
353
Irritable Bowel Syndrome III: Medical and Nursing Management
321
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
321


